TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below.

This change is subject to approval at the 15th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 18, 2020. To strengthen support for auditing by the Audit & Supervisory Committee, the Audit & Supervisory Committee Office was established as of April, 2020, with increased number of full-time staff. The staff of the Audit & Supervisory Committee Office are independent from the Directors who are not the Committee Members and carry out their duties under the direct control of the Audit & Supervisory Committee.

Directors to be retired

Director, Audit & Supervisory Committee Member Tomokazu Fujisawa

Director, Audit & Supervisory Committee Member Hiroko Sakai

Outside Director, Audit & Supervisory Committee Member Noriyuki Uematsu

The Board of Directors as from June 18, 2020 (planned)

Yoshihiko Hatanaka (Representative Director, Chairman of the Board)

Kenji Yasukawa (Representative Director, President and CEO)

Naoki Okamura (Representative Director, Executive Vice President)

Mamoru Sekiyama (Outside Director)

Keiko Yamagami (Outside Director)

Hiroshi Kawabe (Outside Director)

Tatsuro Ishizuka (Outside Director)

Toru Yoshimitsu (Director, Audit & Supervisory Committee Member)

Hiroo Sasaki (Outside Director, Audit & Supervisory Committee Member)

Haruko Shibumura (Outside Director, Audit & Supervisory Committee Member)

Raita Takahashi (Outside Director, Audit & Supervisory Committee Member)

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contact:

Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire